Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
Phase 3 trial data show promising metabolic improvements and durable weight reduction, expanding potential treatment options for millions.
Cycle Pharmaceuticals’ CEO calls approval “a defining moment for patients, physicians and science—proving unmet metabolic needs can be …
New clinical findings support dapiglutide’s potential as first-in-class injectable therapy; CEO touts “milestone in multi-receptor peptide innovation”.
Clinical trial results underscore safety and diagnostic accuracy for radiopharmaceutical imaging; Clarity pursues regulatory filings and wider manufacturing …
: Two radiopharmaceutical candidates gain momentum on 28 May 2025, expanding possibilities in treatment of solid tumors and …
Recent clinical trials are opening new doors for breast cancer treatment, improving accessibility with telehealth and reporting encouraging …
Early-phase trial data for a theranostic radiopharmaceutical, 177Lu-NeoB, demonstrate safety and potential tumour control in patients with GRPR-positive …
Enhertu combo shows promise in metastatic breast cancer while Arvinas reveals hopeful data on a novel lymphoma proteolysis …
New safety and efficacy evidence supports expanded use of mavacamten in oHCM patients
Already a subscriber? Log in